The quarter beat a fairly modest market bar. Published estimates called for roughly $0.72-$0.73 of adjusted EPS and about $388.9 million of revenue; Phibro delivered $0.85 and $396.7 million, respectively, making the earnings upside more meaningful than the revenue beat.
| Metric | Q4 FY26 | Q4 FY25 | FY26 | FY27 guidance | Published expectation |
|---|---|---|---|---|---|
| Revenue | $396.7M | $378.7M | $1,518.1M | $1.55B-$1.60B | ~$388.9M Q4 |
| Adjusted EPS | $0.85 | $0.63 | $3.22 | $3.41-$3.59 | ~$0.72-$0.73 Q4; ~$3.28 FY27 |
| Adjusted EBITDA | $64.2M | $50.0M | $255.0M | $258M-$268M | ~$265M FY27 |
| Adjusted net income | $35.0M | $25.6M | $131.7M | $140M-$147M | — |
| Gross margin | 33.9% | 29.0% | 33.8% | — | — |
| Free cash flow | — | — | $9.9M | — | — |
The quality of the earnings improvement was strong, but not entirely clean. Gross profit rose 22% in the quarter and adjusted gross margin expanded to 34.6%, helped by volume, product mix and a $4.3 million tariff-recovery benefit. Animal Health drove the operating leverage, with quarterly adjusted EBITDA up 25%, while Mineral Nutrition EBITDA was flat.
The underlying trend is better than the headline revenue growth suggests, but the base is changing. Full-year sales increased 17%, largely because the MFA acquisition contributed $146.1 million of incremental revenue; however, fourth-quarter Animal Health sales grew only 2%, and MFA portfolio sales declined year over year. Performance Products also fell 8% for the full year.
FY27 guidance implies continued profit growth, but sharply less acceleration. The midpoint calls for about 4% revenue growth, 3% adjusted EBITDA growth and 9% adjusted net income growth, versus FY26 growth of 17%, 39% and 49%, respectively. The adjusted EPS midpoint of $3.50 is above the roughly $3.28 published estimate, while the EBITDA midpoint of $263 million is slightly below the roughly $265 million expectation—suggesting the outlook is solid but not a broad-based upside reset. 〔0〕
The main offset is execution and cash conversion. Free cash flow was only $9.9 million against $255.0 million of adjusted EBITDA, while total debt stood at $737.9 million and gross leverage at 2.9x. The planned Chicago Heights closure may improve the manufacturing footprint over time, but it affects roughly 100 employees and could create one-time charges excluded from GAAP guidance. 〔1〕
Net read: a genuine earnings beat, with a respectable but more measured outlook. The quarter lands clearly above expectations, and margin expansion supports the result; the slower FY27 growth profile, weak free-cash-flow conversion, higher interest expense and Brazil regulatory uncertainty keep this from being an unqualified upside reset.
Read the original 8-K on SEC EDGAR ↗